

Firm News | January 5, 2021

# Troutman Pepper Advises Inhibikase Therapeutics, Inc. on \$18M IPO

**Company is developing novel treatments for neurological diseases and disorders**

## PRESS CONTACTS

[Diane C. Iselin](#)

## RELATED PROFESSIONALS

[Judith L. O'Grady](#) | [Robert A. Friedel](#) | [Howard J. Shire](#) | [Sheri P. Adler](#) | [Dean Longfield](#) | [Christina M. Boston](#) | [Noreen Hibbard Onimus](#) | [Merrill M. Kraines](#) | [Todd R. Kornfeld](#) | [Kirk Dungca](#) | [David Stauber](#) | [Cagatay Ty Akkoyun](#) | [Jennifer Lang](#) | [Kai Xi \(Echo\) Wang](#) | [Abigail L. Yeo](#)

## RELATED OFFICES

[Atlanta](#)

---

ATLANTA – Troutman Pepper client Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's Disease and related disorders that arise inside and outside of the brain, recently closed its initial public offering (IPO) of 1.8 million shares of common stock at a public price of \$10 per share. [Read a company press release about the IPO.](#)

Inhibikase Therapeutics takes an innovative approach to developing therapeutics for halting and reversing the effects of neurodegenerative diseases inside and outside of the brain, including Parkinson's disease. This approach targets the activation of c-Abl kinase, which the company believes play a significant role in the initiation and progression of neurodegenerative diseases and offers promise for those patients for whom current therapies have not worked.

A team of Troutman Pepper attorneys, led by Partner Merrill Kraines and Counsel Todd Kornfeld as well as Partner [Judy O'Grady](#) and Associate Kirk Dungca, assisted Inhibikase throughout its IPO, advising in the preparation and filing with the Securities and Exchange Commission of its Registration Statement on Form S-1 and amendments thereto, and providing corporate, securities, regulatory, benefits and tax advice.

Other Troutman Pepper attorneys who worked on the IPO included partners [Bob Friedel](#), [David Kaplan](#), [Howard Shire](#), and David Stauber; counsel and registered patent attorney Michael Patané; associates [Sheri Adler](#), [Cagatay Akkoyun](#), [Jennifer Lang](#), [Dean Longfield](#), [Kai Xi Wang](#), and [Abigail Yeo](#); and attorneys [Christina Boston](#) and [Noreen Onimus](#); among others.

Health sciences is a core practice at Troutman Pepper. The firm has more than 150 attorneys who represent clients such as innovative biotech, pharmaceutical and medical device developers and manufacturers; physicians, hospitals and other health care providers; health insurers and other payors; and a wide range of members of the health care supply chain.

## About Troutman Pepper

Troutman Pepper is a national law firm known for its higher commitment to client care. With more than 1,200 attorneys in 23 U.S. cities, the firm partners with clients across every industry sector to help them achieve their business goals. Read more about the firm's litigation, transactional, and regulatory practices at [troutman.com](https://troutman.com).

## RELATED INDUSTRIES + PRACTICES

- [Corporate](#)
- [Health Care + Life Sciences](#)
- [Health Care Transactions](#)
- [Life Sciences Transactions](#)